BioCentury
ARTICLE | Financial News

OptiNose raises $37M in series D round

May 9, 2017 8:16 PM UTC

OptiNose Inc. (Yardley, Pa.) raised $37 million in a series D round led by Fidelity Management & Research Company. Avista Capital Partners, Entrepreneurs Fund and existing investors also participated.

OptiNose's lead candidate OPN-375 is under FDA review to treat nasal polyposis in adults. Its PDUFA date is in September...

BCIQ Company Profiles

OptiNose Inc.

BCIQ Target Profiles

Glucocorticoid receptor (GCCR)